Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex
Aladdin Riad, Chenbo Zeng, Chi-Chang Weng, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 121

Showing 1-25 of 121 citing articles:

The Global Phosphorylation Landscape of SARS-CoV-2 Infection
Mehdi Bouhaddou, Danish Memon, Bjoern Meyer, et al.
Cell (2020) Vol. 182, Iss. 3, pp. 685-712.e19
Open Access | Times Cited: 1013
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
Martí Colom‐Cadena, Tara L. Spires‐Jones, Henrik Zetterberg, et al.
Alzheimer s Research & Therapy (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 249
Structures of the σ2 receptor enable docking for bioactive ligand discovery
Assaf Alon, Jiankun Lyu, João M. Bráz, et al.
Nature (2021) Vol. 600, Iss. 7890, pp. 759-764
Open Access | Times Cited: 151
Comparative profiling of the synaptic proteome from Alzheimer’s disease patients with focus on the APOE genotype
Raphael Hesse, Maica Llavero Hurtado, Rosemary J. Jackson, et al.
Acta Neuropathologica Communications (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
Nicholas J. Izzo, Carla M. Yuede, Kelsie M. LaBarbera, et al.
Alzheimer s & Dementia (2021) Vol. 17, Iss. 8, pp. 1365-1382
Open Access | Times Cited: 71
Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases
Britney N. Lizama, Jennifer Kahle, Susan M. Catalano, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6251-6251
Open Access | Times Cited: 25
Detecting Early Cognitive Decline in Alzheimer’s Disease with Brain Synaptic Structural and Functional Evaluation
Samo Ribarič
Biomedicines (2023) Vol. 11, Iss. 2, pp. 355-355
Open Access | Times Cited: 23
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease
Martí Colom‐Cadena, Jamie Toombs, Elizabeth Simzer, et al.
Acta Neuropathologica (2024) Vol. 147, Iss. 1
Open Access | Times Cited: 13
The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates
Aladdin Riad, Zsofia Lengyel‐Zhand, Chenbo Zeng, et al.
Molecular Neurobiology (2020) Vol. 57, Iss. 9, pp. 3803-3813
Open Access | Times Cited: 62
Lychee seed polyphenol inhibits Aβ-induced activation of NLRP3 inflammasome via the LRP1/AMPK mediated autophagy induction
Wenqiao Qiu, Rong Pan, Yong Tang, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 130, pp. 110575-110575
Open Access | Times Cited: 58
Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective
Antonino N. Fallica, Valeria Pittalà, Maria Modica, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 7926-7962
Open Access | Times Cited: 50
The Sigma Receptors in Alzheimer’s Disease: New Potential Targets for Diagnosis and Therapy
Tao Wang, Hongmei Jia
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12025-12025
Open Access | Times Cited: 18
Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes
Halley M. Oyer, Christina M. Sanders, Felix J. Kim
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 47
TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death
Chenbo Zeng, Chi-Chang Weng, Mark E. Schneider, et al.
Cell Death Discovery (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 46
The Biological Function of Sigma-2 Receptor/TMEM97 and Its Utility in PET Imaging Studies in Cancer
Chenbo Zeng, Aladdin Riad, Robert H. Mach
Cancers (2020) Vol. 12, Iss. 7, pp. 1877-1877
Open Access | Times Cited: 44
PGRMC1 acts as a size-selective cargo receptor to drive ER-phagic clearance of mutant prohormones
Yu-Jie Chen, Jeffrey Knupp, Anoop Arunagiri, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 37
Membrane Progesterone Receptors (mPRs/PAQRs) Are Going beyond Its Initial Definitions
Justin Aickareth, Majd Hawwar, Nickolas Sanchez, et al.
Membranes (2023) Vol. 13, Iss. 3, pp. 260-260
Open Access | Times Cited: 15
Emerging Alzheimer’s disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions
Nour S. Tobeh, Kimberley D. Bruce
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 15
Highly specific σ 2 R/TMEM97 ligand FEM-1689 alleviates neuropathic pain and inhibits the integrated stress response
Muhammad Saad Yousuf, James J. Sahn, Hongfen Yang, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 52
Open Access | Times Cited: 13
An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease
B.N. Lizama, H.A. North, Kiran Pandey, et al.
Neurobiology of Disease (2024) Vol. 199, pp. 106575-106575
Open Access | Times Cited: 5
PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth
Bashar M. Thejer, Partho P. Adhikary, Amandeep Kaur, et al.
BMC Molecular and Cell Biology (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 39
Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain
James Michael Brimson, Sirikalaya Brimson, Chanichon Chomchoei, et al.
Expert Opinion on Therapeutic Targets (2020) Vol. 24, Iss. 10, pp. 1009-1028
Closed Access | Times Cited: 38
Sigma-2 Receptor—A Potential Target for Cancer/Alzheimer’s Disease Treatment via Its Regulation of Cholesterol Homeostasis
Kai Yang, Cheng Zeng, Changcai Wang, et al.
Molecules (2020) Vol. 25, Iss. 22, pp. 5439-5439
Open Access | Times Cited: 35
1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design
Faheem Faheem, Banoth Karan Kumar, Kondapalli Venkata Gowri Chandra Sekhar, et al.
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 10, pp. 1119-1147
Closed Access | Times Cited: 32
Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein
Colleen S. Limegrover, Raymond Yurko, Nicholas J. Izzo, et al.
Journal of Neuroscience Research (2021) Vol. 99, Iss. 4, pp. 1161-1176
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top